I would simply avoid TEAR or look for short-biased trades if after earnings it fails to trigger that breakout and then drops back below its 200-day moving average at $9.80 a share to more near-term support at $9.26 a share with high volume. If we get that move, then TEAR will set up to re-test or possibly take out its next major support levels at $8 to $7 a share, or even $6 a share.
One potential earnings short-squeeze candidate is biopharmaceuticals player Sarepta Therapeutics ( SRPT), which is set to release numbers on Tuesday before the market open. Wall Street analysts, on average, expect Sarepta Therapeutics to report revenue of $4.57 million on a loss of 65 cents per share.
Select the service that is right for you!COMPARE ALL SERVICES
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
- Real Money + Doug Kass Plus 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV